AbCellera

AbCellera (NASDAQ: ABCL) is a Vancouver-based antibody discovery and development company that integrates biology, computation, and engineering to develop antibody-based medicines. Its technology platform combines high-throughput single-cell antibody screening, GPCR and ion-channel capabilities, bispecifics, antibody-drug conjugates, structure-based design, and AI for sequence and structure analysis. The company operates a hybrid business model with a co-development partner network (40+ partners and 100+ antibody drug programs since 2015) alongside a growing wholly-owned pipeline that includes ABCL635 (non-hormonal vasomotor symptoms), ABCL575 (atopic dermatitis), ABCL688 (autoimmunity), and ABCL386 (oncology), plus 20+ discovery programs. AbCellera does not publish a public API or developer portal; capabilities are delivered through partner collaborations and contract terms.

AbCellera is profiled on the APIs.io network. Tagged areas include Antibody Discovery, Biotech, Pharmaceuticals, Monoclonal Antibodies, and Bispecifics.

🌐 Visit website 📡 Source on GitHub

7.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

Antibody DiscoveryBiotechPharmaceuticalsMonoclonal AntibodiesBispecificsAntibody Drug ConjugatesGPCRIon ChannelsSingle CellImmunologyOncologyCeliumPartnershipsVancouver

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 7.4/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/abcellera: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Company 7

The organization behind the API

Website

Website

Partnerships

Partnerships

InvestorRelations

InvestorRelations

Newsroom

Newsroom

Careers

Careers

LinkedIn

Twitter

Twitter

Scroll for all 7

Other 3

Properties that don't map to a standard resource type

Technology

Technology

Pipeline

Pipeline

Publications

Publications

Source (apis.yml)

aid: abcellera
name: AbCellera
description: 'AbCellera (NASDAQ: ABCL) is a Vancouver-based antibody discovery and development company that integrates biology,
  computation, and engineering to develop antibody-based medicines. Its technology platform combines high-throughput single-cell
  antibody screening, GPCR and ion-channel capabilities, bispecifics, antibody-drug conjugates, structure-based design, and
  AI for sequence and structure analysis. The company operates a hybrid business model with a co-development partner network
  (40+ partners and 100+ antibody drug programs since 2015) alongside a growing wholly-owned pipeline that includes ABCL635
  (non-hormonal vasomotor symptoms), ABCL575 (atopic dermatitis), ABCL688 (autoimmunity), and ABCL386 (oncology), plus 20+
  discovery programs. AbCellera does not publish a public API or developer portal; capabilities are delivered through partner
  collaborations and contract terms.'
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/abcellera.png
tags:
- Antibody Discovery
- Biotech
- Pharmaceuticals
- Monoclonal Antibodies
- Bispecifics
- Antibody Drug Conjugates
- GPCR
- Ion Channels
- Single Cell
- Immunology
- Oncology
- Celium
- Partnerships
- Vancouver
url: https://raw.githubusercontent.com/api-evangelist/abcellera/refs/heads/main/apis.yml
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.20'
apis: []
common:
- type: DomainSecurity
  url: security/abcellera-domain-security.yml
- type: Website
  url: https://www.abcellera.com
- type: Technology
  url: https://www.abcellera.com/technology
- type: Pipeline
  url: https://www.abcellera.com/pipeline
- type: Partnerships
  url: https://www.abcellera.com/partnerships
- type: Publications
  url: https://www.abcellera.com/publications
- type: InvestorRelations
  url: https://investors.abcellera.com
- type: Newsroom
  url: https://www.abcellera.com/news
- type: Careers
  url: https://www.abcellera.com/careers
- type: GitHubOrganization
  url: https://github.com/AbCellera
- type: LinkedIn
  url: https://www.linkedin.com/company/abcellera-biologics-inc-
- type: Twitter
  url: https://twitter.com/AbCellera
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com